Akamis Bio Limited
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Psioxus Therapeutics Limited (to 2023)
0
Ending by 2030
Jun 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Oncolytic Adenovirus Encoding a B7 Protein (US 10,322,152) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for A Method of Making Adenovirus and Corresponding Plasmids (US 10,472,648) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Adenovirus Armed with Bispecific T Cell Activator (US 11,840,702) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Oncolytic Adenovirus Encoding a Therapeutic Protein or Active Fragment (US 10,548,929) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Sep 26, 2027The maintenance fee for Oncolytic Adenoviruses Armed with Heterologous Genes (US 11,938,159) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Group B Adenovirus Encoding an Anti-Tcr-Complex Antibody or Fragment (US 11,970,536) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,173,186 | A Dosing Regime and Formulations for Type B Adenovirus In force · High confidence | In force | High confidence | |
| US 12,350,302 | Dosing Regime and Formulations for Type B Adenoviruses In force · High confidence | In force | High confidence | |
| US 9,987,314 | Oncolytic Adenoviruses Armed with Heterologous Genes In force · High confidence | In force | High confidence | |
| US 10,034,905 | Group B Adenovirus Modified in the E4ORF4 Region In force · High confidence | In force | High confidence | |
| US 11,439,678 | Oncolytic Adenoviruses Armed with Heterologous Genes In force · Low confidence | In force | Low confidence | |
| US 10,472,648 | A Method of Making Adenovirus and Corresponding Plasmids In force · High confidence | In force | High confidence | |
| US 12,653,852 | Oncolytic Adenoviruses Armed with Heterologous Genes In force · Medium confidence | In force | Medium confidence | |
| US 11,938,159 | Oncolytic Adenoviruses Armed with Heterologous Genes In force · Medium confidence | In force | Medium confidence | |
| US 10,322,152 | Oncolytic Adenovirus Encoding a B7 Protein In force · High confidence | In force | High confidence | |
| US 11,000,559 | Oncolytic Adenovirus Encoding a B7 Protein In force · High confidence | In force | High confidence |
Also on record, not counted in the 20: 1 patent in force now held by others · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending